Experimental drug RAD001 tested for tough leukemias and lymphomas
NCT ID NCT00081874
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a single cancer center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RAD001 (everolimus, Afinitor)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with hard-to-treat blood cancers.
- What could go wrong
- This is an early-phase trial with only 29 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Talking about the end: could guided conversations reduce futile cancer treatments?